12 October 2017 | Heterozygous RFX6 protein truncating variants are associated with MODY with reduced penetrance | Patel, KA; Kettunen, J; Laakso, M; et al. |
16 July 2017 | Neuropsychological impairments in children with KCNJ11 neonatal diabetes | Bowman, P; Hattersley, AT; Knight, BA; et al. |
5 August 2017 | Screening for neonatal diabetes at day 5 of life using dried blood spot glucose measurement. | McDonald, TJ; Besser, RE; Perry, M; et al. |
31 March 2016 | Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes | Babiker, T; Vedovato, N; Patel, K; et al. |
1 September 2016 | Prematurity should not prevent genetic testing for neonatal diabetes | Besser, RE; Flanagan, SE; Mackay, DG; et al. |
11 April 2016 | Psychiatric morbidity in children with KCNJ11 neonatal diabetes | Bowman, P; Broadbridge, E; Knight, BA; et al. |
30 October 2018 | Cognitive, Neurological, and Behavioral Features in Adults With KCNJ11 Neonatal Diabetes | Bowman, P; Day, J; Torrens, L; et al. |
4 June 2018 | Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study | Bowman, P; Sulen, Å; Barbetti, F; et al. |
7 February 2017 | Hyperglycaemia-related complications at the time of diagnosis can cause permanent neurological disability in children with neonatal diabetes | Day, JO; Flanagan, SE; Shepherd, MH; et al. |
4 June 2018 | Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study | Bowman, P; Sulen, Å; Barbetti, F; et al. |